P. Schöffski

Gemcitabine in Patients With Relapsed or Cisplatin-Refractory Testicular Cancer

Carsten Bokemeyer, A. Gerl, P. Schöffski et al. · Journal of Clinical Oncology · 1999 · 139 citations

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group

P. Schöffski, S. Riggert, P. Fumoleau et al. · Annals of Oncology · 2004 · 78 citations · Full text

Surgical Oncology, Solid Tumors, Medicine +9

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

P. Schöffski, Benjamin Besse, Thomas Gauler et al. · Annals of Oncology · 2014 · 55 citations · Full text

Non-small-cell Lung Cancer, Biweekly I.v, Medicine +9

Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer.

Debbie Debaere, Vincent Vander Poorten, Sandra Nuyts et al. · PubMed · 2011 · 44 citations

A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC)

José Baselga, P. Schöffski, Federico Rojo et al. · Journal of Clinical Oncology · 2006 · 38 citations

Oral Daily G, Pathology, Pharmacotherapy +16